Stock Traders Purchase High Volume of Invivyd Call Options (NASDAQ:IVVD)

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) saw some unusual options trading on Thursday. Stock traders purchased 2,267 call options on the company. This represents an increase of 463% compared to the typical daily volume of 403 call options.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. EF Hutton Acquisition Co. I raised shares of Invivyd to a "strong-buy" rating in a report on Wednesday, October 30th. Morgan Stanley decreased their price target on shares of Invivyd from $9.50 to $3.55 and set an "overweight" rating on the stock in a report on Wednesday, November 20th. HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Invivyd in a research note on Tuesday, February 4th. Finally, D. Boral Capital restated a "buy" rating and set a $9.00 target price on shares of Invivyd in a research report on Monday, February 3rd. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $7.89.

Insider Activity at Invivyd

In other Invivyd news, Director Terrance Mcguire sold 160,400 shares of Invivyd stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $0.59, for a total transaction of $94,636.00. Following the completion of the transaction, the director now owns 4,202,679 shares of the company's stock, valued at $2,479,580.61. The trade was a 3.68 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last three months, insiders have sold 816,466 shares of company stock worth $423,214. 17.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Invivyd

A number of hedge funds have recently made changes to their positions in the business. State Street Corp increased its stake in Invivyd by 3.7% in the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company's stock worth $1,039,000 after purchasing an additional 35,904 shares during the period. Barclays PLC lifted its holdings in Invivyd by 179.6% in the third quarter. Barclays PLC now owns 117,973 shares of the company's stock worth $120,000 after buying an additional 75,780 shares during the period. Cubist Systematic Strategies LLC boosted its position in shares of Invivyd by 66.1% during the second quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company's stock valued at $148,000 after purchasing an additional 53,499 shares in the last quarter. Renaissance Technologies LLC bought a new stake in shares of Invivyd during the 2nd quarter valued at $421,000. Finally, Proficio Capital Partners LLC bought a new stake in Invivyd during the third quarter worth about $27,000. 70.36% of the stock is currently owned by institutional investors.

Invivyd Stock Down 23.3 %

Shares of Invivyd stock traded down $0.48 during trading on Monday, hitting $1.57. 18,158,010 shares of the stock traded hands, compared to its average volume of 29,976,670. Invivyd has a 52 week low of $0.35 and a 52 week high of $4.74. The firm's fifty day moving average is $0.60 and its 200-day moving average is $0.84. The stock has a market cap of $187.21 million, a price-to-earnings ratio of -0.80 and a beta of 0.61.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.